Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

180
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
180
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

142
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
142
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

197
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
197
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

153
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
153
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: A Lethal Progressive Neuroinflammation Disguised as MOGAD Revealing a Final Diagnosis of Griscelli Syndrome: Regarding: MOGAD is the Most Common Cause of Isolated Optic Neuritis in Children.

Annals of clinical and translational neurology·2026
Same author

Adaptation of the Transition Readiness Assessment Questionnaire for Pediatric-Onset Multiple Sclerosis: Protocol for a User-Centered Design Approach.

JMIR research protocols·2026
Same author

New-onset refractory status epilepticus/febrile infection-related epilepsy syndrome centers of excellence: A framework for coordinated care, research, and improved outcomes.

Epilepsia·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children.

Annals of clinical and translational neurology·2026
Same author

Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitis.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K

Current Advances in Pediatric Onset Multiple Sclerosis.

Kristen S Fisher1, Fernando X Cuascut2, Victor M Rivera2

  • 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA.

Biomedicines
|April 2, 2020
PubMed
Summary
This summary is machine-generated.

Pediatric multiple sclerosis (MS) diagnosis and treatment have advanced, with earlier interventions and higher-efficacy therapies now standard for managing this rare central nervous system disease in children.

Keywords:
child neurologydemyelinating diseasemultiple sclerosisneuroimmunologypediatric multiple sclerosispediatric neurology

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.4K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.3K

Related Experiment Videos

Last Updated: Dec 25, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.4K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.3K

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Multiple sclerosis (MS) is a rare autoimmune inflammatory central nervous system disease causing demyelination.
  • Pediatric MS can lead to significant long-term disability.
  • Advances in diagnosis and treatment are crucial for managing pediatric MS.

Purpose of the Study:

  • To review current knowledge on the diagnosis of pediatric MS.
  • To discuss contemporary treatment strategies, including disease-modifying therapies (DMTs).
  • To examine clinical outcomes in children and adolescents with MS.

Main Methods:

  • Literature review of recent studies on pediatric MS.
  • Analysis of diagnostic criteria evolution.
  • Evaluation of treatment trends and efficacy of DMTs.

Main Results:

  • Improved diagnostic criteria enable earlier MS diagnosis in pediatric patients.
  • Treatment patterns have shifted towards earlier initiation of high-efficacy DMTs.
  • Evidence supports using more potent therapies to prevent disease progression.

Conclusions:

  • Earlier diagnosis and treatment initiation are key in pediatric MS management.
  • High-efficacy DMTs are increasingly used at diagnosis to mitigate disability.
  • Ongoing research is vital for optimizing long-term outcomes in pediatric MS.